Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 19, Issue 2, 2005, Pages 25-31

  Zimmermann, Camilla ^a   Seccareccia, Dori ^a   Booth, Christopher M ^b   Cottrell, Wayne ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer pain; Hydromorphone; Methadone; Opioid dose escalation; Opioid rotation; Opioid tolerance; Opioid toxicity

Indexed keywords

CISPLATIN; CLONAZEPAM; DESIPRAMINE; DEXAMETHASONE; GABAPENTIN; GEMCITABINE; HYDROMORPHONE; LONG ACTING DRUG; MELOXICAM; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; BACKACHE; BONE METASTASIS; CANCER PAIN; CANCER PALLIATIVE THERAPY; CASE REPORT; DELIRIUM; DOSE CALCULATION; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; INDIVIDUALIZATION; LEG PAIN; LEIOMYOSARCOMA; MYOCLONUS; NEUROPATHIC PAIN; NEUROTOXICITY; RESPIRATION DEPRESSION; URETER CANCER;

ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROMORPHONE; METHADONE; MIDDLE AGED; NEOPLASMS; NEUROTOXICITY SYNDROMES; PAIN, INTRACTABLE; PALLIATIVE CARE;

EID: 25144518253     PISSN: 15360288     EISSN: None     Source Type: Journal    
DOI: 10.1300/J354v19n02_05     Document Type: Article

References (31)

1. Watanabe, S. Methadone: The Renaissance. Journal of Palliative Care 2001;17(2):117-20.
2. Bruera, E. and Sweeney, C. Methadone Use in Cancer Patients with Pain: A Review. Journal of Palliative Medicine 2002;5(1):127-37.
3. Gazelle, G. and Fine, P. G. Methadone for Pain: #75. Journal of Palliative Medicine 2004;7(2):303-304.
4. von Gunten, C. F. Methadone: Starting Dosing Information #86. Journal of Palliative Medicine 2004;7(2):304-305.
5. Bruera, E., Palmer, J. L., Bosnjak, S., Rico, M. A., Moyano, J., Sweeney, C., Strasser, F., Willey, J., Bertolino, M., Mathias, C., Spruyt, O., and Fisch, Mi. Methadone Versus Morphine as a First-Line Strong Opioid for Cancer Pain: A Randomized, Double-Blind Study. Journal of Clinical Oncology 2004:22(1):185-92.
6. Morley, J. S. and Makin, M. K. The Use of Methadone in Cancer Pain Poorly Responsive to Other Opioids. Pain Reviews 1998;5:51-8.
7. Mercadente, S., Casuccio, A., Fulfaro, F., Groff, L., Boffi, R., Villari, P., Gebbia, V., and Ripamonti, C. Switching from Morphine to Methadone to Improve Analgesia and Tolerability in Cancer Patients: A Prospective Study. Journal of Clinical Oncology 2001;19(11):2898-904.
8. Inturissi, C. E. Clinical Pharmacology of Opioids for Pain. The Clinical Journal of Pain 2002;18(4):53-513.
9. Hanks, G. and Cherry, N. Opioid Analgesic Therapy. Doyle, D., Hanks, G. W. C., and MacDonald, N. Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press; 1998. pp. 331-55.
10. Bruera, E. D., Pereira, J., Watanabe, S., Belzile, M., Kuehn, N., and Hanson, J. Opioid Rotation in Patients with Cancer Pain. A Retrospective Comparison of Dose Ratios Between Methadone, Hydromorphone and Morphine. Cancer 1996;78(4):852-7.
11. Ripamonti, C., De Conno, F., Groff, L., Belzile, M., Pereira, J., hanson, J., and Bruera, E. Equianalgesic Dose/Ratio Between Methadone and Other Opioid Agonists in Cancer Pain: Comparison of Two Clinical Experiences. Annals of Oncology 1998;9:79-83.
12. Lawlor, P. G., Turner, K. S., Hanson, J., and Bruera, E. D. Dose Ratio Between Morphine and Methadone in Patients with Cancer Pain. A Retrospective Study. Cancer 1998;82(6):1167-73.
13. Ripamonti, C., Groff, L., Brunelli, C., Polastri, D., Stavrakis, A., and De Conno, F. Switching from Morphine to Oral Methadone in Treating Cancer Pain: What Is the Equianalgesic Dose Ratio? Journal of Clinical Oncology 1998;16(10):3216-21.
14. Hanks, G. and Justins, D. Cancer Pain: Management. Lancet 1992;339:1031-6.
15. Indelicato, R. A. and Portenoy, R. K. Opioid Rotation in the Management of Refractory Cancer Pain. Journal of Clinical Oncology 2003;21(9):87s-91s.
16. Mercadente, S. Opioid Rotation for Cancer Pain. Rationale and Clinical Aspects. Cancer 1999;86(9):1856-66.
17. Mercadente, S., Ferrera, P., Villari, P., and Arcuri, E. Hyperalgesia: An Emerging Iatrogenic Syndrome. Journal of Pain and Symptom Manage ment 2003;26(2):769-75.
18. Dickerson, D. E. Methadone: The Question or the Answer for US Opioid Therapy and Pharmaco-Economics? Supportive Care in Cancer 2001;9:646-7.
19. Davis, M. P. and Walsh, D. Methadone for Relief of Cancer Pain: A Review of Pharmacokinetics. Pharmacodynamics, Drug Interactions and Protocols of Administration. Supportive Care in Cancer 2001;9:73-83.
20. Bruera, E., Watanabe, S., Fainsinger, R. L., Spachynski, K., Suarez-Almazor, M., and Inturissi, C. E. Custom-Made Capsules and Suppositories of Methadone for Patients on High-Dose Opioids for Cancer Pain. Pain 1995;62:141-6.
21. Anderson, R., Saiers, J. H., Abram, S., and Schlicht, C. Accuracy in Equianalgesic Dosing: Conversion Dilemmas. Journal of Pain and Symptom Management 2001;21(5):397-406.
22. Pereira, J., Lawlor, P., Vigano, A., Dorgan, M., and Bruera, E. Equianalgesic Dose Ratios for Opioids: A Critical Review and Proposals for Long-Term Dosing. Journal of Pain and Symptom Management 2001;22(2):672-87.
23. Xu, X., Colpaert, F., and Wiesenfel-Hallin, Z. Opioid Hyperalgesia and Tolerance Versus 5-HT 1A Receptor-Mediated Inverse Tolerance. Trends in Pharmacological Sciences 2003;24(12):634-9.
24. Mao, J., Price, D. D., and Mayer, D. J. Mechanisms of Hyperalgesia and Morphine Tolerance: A Current View of Their Possible Interactions. Pain 1995;62:259-74.
25. Sartain, J. B. and Mitchell, S. J. Successful Use of Oral Methadone After Failure of Intravenous Morphine and Ketamine. Anaesthesia and Intensive care 2002;30(4):487-9.
26. Stevenson, G. W., Folk, J. E., Linsenmayer, D. C., Rice, K. C., and Negus, S. S. Opioid Interactions in Rhesus Monkeys: Effects of Delta + Mu and Delta + Kappa Agonists on Schedule-Controlled Responding and Thermal Nociception. Journal of Experimental Therapeutics 2003;307(3):1054-64.
27. Liu, J. G., Liao, X. P., Gong, Z. H., and Qin, B. Y. Methadone-Induced Desensitization of the Delta-Opioid Receptor Is Mediated by Uncoupling of Receptor from G-Protein. European Journal of Pharmacology 1999;374(2):301-8.
28. Codd, E. E., Shank, R. P., Schupsky, J. J., and Raffa, R. B. Serotonin and Norepinephrine Uptake Inhibiting Activity of Centrally Acting Analgesics: Structural Determinants and Role in Antinociception. Journal of Pharmacology and Experimental Therapeutics 1995;274(3):1263-70.
29. Smith, M. T. Neuroexcitatory Effects of Morphine and Hydromorphone: Evidence Implicating the 3-Glucuronide Metabolites. Clinical and Experimental Pharmacology and Physiology 2000;27:524-8.
30. Wright, A. W. E., Mather, L. E., and Smith, M. T. Hydromorphone-3 Glucuronide: A More Potent Neuro-Excitant Than Its Structural Analogue, Morphine-3-Glucuronide. Life Sciences 2001;69:409-20.
31. Davis, M. P. Methadone As a Rescue for Failed High-Dose Opiate Therapy for Catastrophic Pain. Supportive Care in Cancer 2000;8:138-40.